OTLK Stock Overview
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Outlook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.01 |
| 52 Week High | US$18.00 |
| 52 Week Low | US$4.09 |
| Beta | 0.64 |
| 11 Month Change | 9.13% |
| 3 Month Change | 6.09% |
| 1 Year Change | 84.14% |
| 33 Year Change | -83.38% |
| 5 Year Change | -76.63% |
| Change since IPO | -98.83% |
Recent News & Updates
Recent updates
Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?
Nov 03
Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%
Aug 30Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01
Aug 10Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?
Jul 06Outlook Therapeutics announces full cash pre-payment of convertible promissory note
Jul 05Outlook Therapeutics: A One-Buck Lottery Ticket
Jun 09Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?
Apr 01Outlook Therapeutics: Likely FDA Approval, Possible Buyout
Jan 21Shareholder Returns
| OTLK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.8% | -1.9% | -3.4% |
| 1Y | 84.1% | 13.9% | 19.6% |
Return vs Industry: OTLK exceeded the US Biotechs industry which returned 13.9% over the past year.
Return vs Market: OTLK exceeded the US Market which returned 19.6% over the past year.
Price Volatility
| OTLK volatility | |
|---|---|
| OTLK Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OTLK has not had significant price volatility in the past 3 months.
Volatility Over Time: OTLK's weekly volatility has decreased from 18% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 24 | Russ Trenary | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte.
Outlook Therapeutics, Inc. Fundamentals Summary
| OTLK fundamental statistics | |
|---|---|
| Market cap | US$189.48m |
| Earnings (TTM) | -US$94.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs OTLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTLK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$34.18m |
| Gross Profit | -US$34.18m |
| Other Expenses | US$59.86m |
| Earnings | -US$94.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -38.8% |
How did OTLK perform over the long term?
See historical performance and comparison